Optimal Patient Selection and Treatment Timing for Tolvaptan Therapy Following Cardiovascular Surgery.
作者信息
Horie Kotaro, Imamura Teruhiko
机构信息
Second Department of Internal Medicine, University of Toyama Toyama Japan.
出版信息
Circ Rep. 2023 Feb 25;5(3):101. doi: 10.1253/circrep.CR-23-0002. eCollection 2023 Mar 10.
Abstract
摘要
相似文献
1
Optimal Patient Selection and Treatment Timing for Tolvaptan Therapy Following Cardiovascular Surgery.心血管手术后托伐普坦治疗的最佳患者选择及治疗时机
Circ Rep. 2023 Feb 25;5(3):101. doi: 10.1253/circrep.CR-23-0002. eCollection 2023 Mar 10.
2
Optimal Patient Selection and Treatment Timing for Tolvaptan Therapy Following Cardiovascular Surgery - Reply.心血管手术后托伐普坦治疗的最佳患者选择和治疗时机——回复
Circ Rep. 2023 Feb 25;5(3):102. doi: 10.1253/circrep.CR-23-0014. eCollection 2023 Mar 10.
3
Advent of New perioperative care for fluid management after cardiovascular surgery: A review of current evidence.心血管手术后新围手术期液体管理的出现：当前证据综述。
J Cardiol. 2020 Jun;75(6):606-613. doi: 10.1016/j.jjcc.2019.12.010. Epub 2020 Jan 22.
4
Predictive factors for responders to tolvaptan in fluid management after cardiovascular surgery.心血管手术后液体管理中托伐普坦反应者的预测因素。
Gen Thorac Cardiovasc Surg. 2017 Feb;65(2):110-116. doi: 10.1007/s11748-016-0712-6. Epub 2016 Sep 19.
5
Clinical Effects of Early and Short-Term Tolvaptan Administration in Patients Hospitalized for Acute Decompensated Heart Failure.急性失代偿性心力衰竭住院患者早期及短期应用托伐普坦的临床疗效
Cardiology. 2021;146(6):739-747. doi: 10.1159/000518732. Epub 2021 Aug 3.
6
Peak Lag Between Plasma Vasopressin and Urine Aquaporin-2 Following Cardiac Surgery.心脏手术后血浆血管加压素与尿水通道蛋白 2 的最大滞后。
Int Heart J. 2021 Sep 30;62(5):1057-1061. doi: 10.1536/ihj.21-301. Epub 2021 Sep 17.
7
Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio.通过简单易得的随机尿钠/钾比值预测托伐普坦的利尿反应。
PLoS One. 2017 Mar 31;12(3):e0174649. doi: 10.1371/journal.pone.0174649. eCollection 2017.
8
Efficacy of Tolvaptan on Fluid Management After Cardiovascular Surgery Using Cardiopulmonary Bypass.托伐普坦对体外循环心血管手术后液体管理的疗效
J Cardiothorac Vasc Anesth. 2016 Dec;30(6):1471-1478. doi: 10.1053/j.jvca.2016.06.013. Epub 2016 Jun 15.
9
Effects of Low-Dose Tolvaptan for Fluid Management After Cardiovascular Surgery.小剂量托伐普坦对心血管手术后液体管理的影响。
Circ Rep. 2022 Nov 11;4(12):563-570. doi: 10.1253/circrep.CR-22-0107. eCollection 2022 Dec 9.
10
Efficacy and Safety Evaluation of Tolvaptan on Management of Fluid Balance after Cardiovascular Surgery Using Cardiopulmonary Bypass.托伐普坦对体外循环心血管手术后液体平衡管理的疗效及安全性评估
Osaka City Med J. 2016 Dec;62(2):111-119.
本文引用的文献
1
Effects of Low-Dose Tolvaptan for Fluid Management After Cardiovascular Surgery.小剂量托伐普坦对心血管手术后液体管理的影响。
Circ Rep. 2022 Nov 11;4(12):563-570. doi: 10.1253/circrep.CR-22-0107. eCollection 2022 Dec 9.
2
Peak Lag Between Plasma Vasopressin and Urine Aquaporin-2 Following Cardiac Surgery.心脏手术后血浆血管加压素与尿水通道蛋白 2 的最大滞后。
Int Heart J. 2021 Sep 30;62(5):1057-1061. doi: 10.1536/ihj.21-301. Epub 2021 Sep 17.
3
Update of acute and long-term tolvaptan therapy.托伐普坦的急性和长期治疗更新。
J Cardiol. 2019 Feb;73(2):102-107. doi: 10.1016/j.jjcc.2018.10.003. Epub 2018 Nov 9.
4
Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure.与血浆精氨酸加压素相比，尿水通道蛋白-2增加是失代偿性心力衰竭患者对托伐普坦反应的一种新标志物。
Circ J. 2014;78(9):2240-9. doi: 10.1253/circj.cj-14-0244. Epub 2014 Jun 20.
Zotero 插件